<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-06-09">9 June 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Maria</forename><surname>Joosten</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sebastian</forename><surname>Ginzel</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Department of Computer Science</orgName>
								<orgName type="institution">Bonn-Rhine-Sieg University of Applied Sciences</orgName>
								<address>
									<addrLine>Grantham-Allee 20</addrLine>
									<postCode>53757</postCode>
									<settlement>Sankt Augustin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><surname>Blex</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dmitri</forename><surname>Schmidt</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Gombert</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cai</forename><surname>Chen</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Clinic for Gastroenterology, Hepatology and Infectiology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstrasse 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Linka</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Olivia</forename><surname>Gr</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anika</forename><surname>Hain</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Clinic for Gastroenterology, Hepatology and Infectiology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstrasse 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Burkhard</forename><surname>Hirsch</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anke</forename><surname>Sommerfeld</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anke</forename><surname>Seegebarth</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Uschi</forename><surname>Gruber</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Corinna</forename><surname>Maneck</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Langhui</forename><surname>Zhang</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department" key="dep1">Department of Hematology</orgName>
								<orgName type="department" key="dep2">Fujian Province</orgName>
								<orgName type="institution" key="instit1">Union Hospital</orgName>
								<orgName type="institution" key="instit2">Fujian Medical University</orgName>
								<address>
									<addrLine>NO.29, Xinquan Road</addrLine>
									<settlement>Fuzhou City</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katharina</forename><surname>Stenin</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henrik</forename><surname>Dieks</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Sefkow</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Carsten</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Clinic for Gastroenterology, Hepatology and Infectiology</orgName>
								<orgName type="department" key="dep2">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstrasse 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Claudia</forename><forename type="middle">D</forename><surname>Baldus</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ralf</forename><surname>Thiele</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Computer Science</orgName>
								<orgName type="institution">Bonn-Rhine-Sieg University of Applied Sciences</orgName>
								<address>
									<addrLine>Grantham-Allee 20</addrLine>
									<postCode>53757</postCode>
									<settlement>Sankt Augustin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arndt</forename><surname>Borkhardt</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Hummel</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ute</forename><surname>Fischer</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Pediatric Oncology, Hematology and Clinical Immunology</orgName>
								<orgName type="department" key="dep2">Center of Child and Adolescent Health</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Medical Faculty</orgName>
								<orgName type="institution">Heinrich-Heine-University</orgName>
								<address>
									<addrLine>Moorenstr. 5, 40225 D€ usseldorf</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mathias</forename><surname>Dreger</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">caprotec bioanalytics GmbH</orgName>
								<address>
									<addrLine>Magnusstraße 11</addrLine>
									<postCode>12489</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Volkhard</forename><surname>Seitz</surname></persName>
							<email>volkhard.seitz@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="department">Institute of Pathology</orgName>
								<orgName type="institution">Charit e University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12000</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-06-09">9 June 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">030D248B42C7318627ED2F6929D176BB</idno>
					<idno type="DOI">10.1016/j.molonc.2016.06.001</idno>
					<note type="submission">Received 15 January 2016 Received in revised form 2 June 2016 Accepted 3 June 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:21+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>SAHA HDAC inhibitor FGR B-cell lymphoma</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Histone deacetylase (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are not commonly used in clinical practice for treatment of B-cell lymphomas, although a subset of patients with refractory or relapsed B-cell lymphoma achieved partial or complete remissions.</s></p><p><s>Therefore, the purpose of this study was to identify molecular features that predict the response of B-cell lymphomas to SAHA treatment.</s><s>We designed an integrative approach combining drug efficacy testing with exome and captured target analysis (DETECT).</s><s>In this study, we tested SAHA sensitivity in 26 B-cell lymphoma cell lines and determined Abbreviations: BL, Burkitt lymphoma; CC, capture compound; CCMS, capture compound mass spectrometry; CRISPR, Clustered Regularly Interspaced Short Palindromic Repeats; DETECT, drug efficacy testing combined with exome and captured target analysis; DLBCL, diffuse large B-cell lymphoma; FGR, Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog; HDAC, histone deacetylase; IC 50 , half maximal inhibitory concentration; NHL, Non-Hodgkin lymphoma; SAHA, suberoylanilide hydroxamic acid.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Introduction</head><p><s>During the past decades, epigenetics has emerged as an important area in drug discovery.</s><s>So called "epidrugs" are defined as drugs that inhibit or activate disease-associated epigenetic proteins to ameliorate or cure the disease <ref type="bibr" target="#b22">(Ivanov et al., 2014)</ref>.</s><s>Especially inhibitors of histone deacetylases (HDAC) are considered to be promising anticancer agents.</s><s>By regulating acetylation states of histone and several nonhistone proteins, they directly induce modifications in the cancer epigenome.</s><s>Thereby, epigenetically silenced genes are re-expressed eventually resulting in growth arrest or apoptosis of cancer cells <ref type="bibr" target="#b3">(Carew et al., 2008)</ref>.</s><s>Due to this antitumor activity, HDAC inhibitors had a rapid phase of clinical development as monotherapy and in combination with other anticancer drugs <ref type="bibr" target="#b2">(Budde et al., 2013;</ref><ref type="bibr" target="#b28">Kirschbaum et al., 2011;</ref><ref type="bibr" target="#b34">Morschhauser et al., 2015;</ref><ref type="bibr" target="#b36">Ogura et al., 2014;</ref><ref type="bibr" target="#b37">Oki et al., 2013;</ref><ref type="bibr" target="#b48">Straus et al., 2015;</ref><ref type="bibr" target="#b53">Watanabe et al., 2010)</ref>.</s><s>However, a broad clinical response has been observed in patients with hematologic or solid malignancies ranging from complete remissions to no response <ref type="bibr" target="#b5">(Chun, 2015)</ref>.</s><s>Suberoylanilide hydroxamic acid (SAHA) (Vorinostat, Zolinza Ò (Merck and Co., Inc.)) was the first HDAC inhibitor approved by the American Food and Drug Administration in October 2006 for the treatment of a subset of patients with cutaneous T-cell lymphoma <ref type="bibr" target="#b32">(Mann et al., 2007)</ref>.</s><s>Furthermore, SAHA is also used in clinical trials for patients with other types of Non-Hodgkin lymphoma (NHL) <ref type="bibr" target="#b2">(Budde et al., 2013;</ref><ref type="bibr" target="#b28">Kirschbaum et al., 2011;</ref><ref type="bibr" target="#b36">Ogura et al., 2014;</ref><ref type="bibr" target="#b48">Straus et al., 2015;</ref><ref type="bibr" target="#b53">Watanabe et al., 2010)</ref>.</s></p><p><s>NHL is a heterogeneous group of lymphoproliferative neoplasms.</s><s>Two aggressive subtypes of B-cell NHLs are diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL), which account for 40% and 2% of all NHLs, respectively <ref type="bibr" target="#b47">(Siegel et al., 2015;</ref><ref type="bibr" target="#b50">Swerdlow et al., 2008)</ref>.</s><s>Although survival of patients with B-cell lymphoma has improved by the addition of targeted therapies to conventional chemotherapy regimens, a considerable proportion relapse leading to adverse clinical outcome <ref type="bibr" target="#b6">(Coiffier et al., 2010;</ref><ref type="bibr" target="#b19">Hoelzer et al., 2014;</ref><ref type="bibr" target="#b39">Reeder and Ansell, 2011;</ref><ref type="bibr" target="#b49">Sweetenham et al., 1996)</ref>.</s><s>Thus, novel approaches are urgently needed to improve disease control and patient's survival.</s><s>More specific and therefore less toxic treatment opportunities would be highly desirable <ref type="bibr" target="#b5">(Chun, 2015)</ref>.</s><s>Preclinical and clinical studies with SAHA mono-or combination therapies showed promising results for the treatment of patients with B-cell lymphoma <ref type="bibr" target="#b28">(Kirschbaum et al., 2011;</ref><ref type="bibr" target="#b36">Ogura et al., 2014;</ref><ref type="bibr" target="#b41">Richter-Larrea et al., 2010;</ref><ref type="bibr" target="#b53">Watanabe et al., 2010)</ref>.</s><s>Remarkably, response rates of up to 30% were achieved in patients with relapsed or refractory B-cell lymphoma upon SAHA monotherapy, comprising also complete remissions <ref type="bibr" target="#b28">(Kirschbaum et al., 2011;</ref><ref type="bibr" target="#b36">Ogura et al., 2014;</ref><ref type="bibr" target="#b53">Watanabe et al., 2010)</ref>.</s><s>70% of patients, however, do not respond to this treatment.</s><s>Therefore, it is essential to identify those patients who will not benefit from HDAC inhibitor therapy in order to prevent ineffective treatment.</s></p><p><s>These clinical data stimulated us to seek for molecular features that help to stratify upfront B-cell lymphoma patients for SAHA treatment.</s><s>To this end, we hypothesized (i) that proteins, which directly interact with SAHA, may be involved in SAHA response and (ii) that the expression and mutation status of these direct SAHA targets might be of relevance for SAHA response.</s></p><p><s>Direct SAHA interaction partners can be identified by Capture Compound Mass Spectrometry (CCMS).</s><s>CCMS is based on a trifunctional small molecular probe called Capture Compounds (CC).</s><s>SAHA is attached as selectivity function to a CC-scaffold that can interact with the target proteins in homogeneous phase under equilibrium conditions.</s><s>The reactivity function of the CC-scaffold covalently binds the target proteins through photo-induced cross-linking.</s><s>The sorting function of the CC-scaffold (e.g.</s><s>biotin) enables the isolation of CC-proteins conjugates from complex protein mixtures <ref type="bibr">(Supplemental Figures. S1 and S2)</ref>.</s><s>Finally, captured proteins are identified using high-resolution mass spectrometry <ref type="bibr" target="#b14">(Fischer et al., 2011b;</ref><ref type="bibr" target="#b29">Koster et al., 2007)</ref>.</s></p><p><s>To comprehensively identify the molecular mechanisms leading to SAHA resistance we designed an approach that applies drug efficacy testing with exome and captured target analysis (DETECT; Figure <ref type="figure">1</ref>).</s><s>In detail, we combined (i) determination of SAHA sensitivity in 26 B-cell lymphoma cell lines by flow cytometry (Annexin V/propidium iodide staining) with (ii) analysis of exome mutations, (iii) CCMS of direct SAHA binders in SAHA resistant versus sensitive B-cell lymphoma cell lines and (iv) performed an integrated network analysis.</s><s>For further candidate validation, we carried out expression analysis and knock-out experiments.</s><s>To provide evidence for clinical relevance, in silico expression and mutation analysis of published data derived from B-cell lymphoma patients were performed.</s></p><p><s>Our DETECT approach led to the identification of SAHAinteracting protein networks and highlights the Src tyrosine kinase FGR as a factor mediating SAHA resistance in B-cell lymphoma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1.">Human cell lines and culture</head><p><s>26 human B-cell lymphoma cell lines (16 DLBCL and 10 BL cell lines) were used in this study, which were obtained from DSMZ or kindly provided by Georg Lenz.</s><s>Details about cell lines and culture conditions are given in Supplemental Methods (section 1.1) and in Supplemental Table <ref type="table" target="#tab_0">1</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2.">SAHA efficacy testing</head><p><s>26 B-cell lymphoma cell lines were seeded in triplicates into 12 well plates at a density of 3 Â 10 5 cells per well and treated with either vehicle (DMSO) or varying concentrations (0.03 mM, 0.06 mM, 0.12 mM, 0.25 mM, 0.5 mM, 1 mM, 2 mM, 4 mM, 8 mM, 16 mM, 32 mM) of the HDAC inhibitor SAHA (Cayman Chemical) for 48 h.</s><s>Subsequently, apoptosis was determined by flow cytometry (Accuri C6; Becton, Dickinson and Company (BD)) using the APC Annexin V Apoptosis Detection Kit with propidium iodid (PI) (Biolegend) according to the manufacturer's instructions.</s><s>Data were analyzed employing Accuri C6 software (BD).</s><s>The inhibitory concentration IC 50 was defined as the concentration of SAHA needed to decrease cell viability by 50%.</s><s>Data were analyzed using Prism 6 (GraphPad Software, Inc.).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3.">Cellular protein extraction and CCMS experiments</head><p><s>Cells were lysed in buffer containing 20 mM HEPES/NaOH pH 7.4, 250 mM sucrose, 5 mM MgCl 2 , 1 mM DTT, 0.5% (w/v) ndodecyl-b-maltoside supplemented with completeä protease inhibitor cocktail (Roche) and benzonase using a glasseglass douncer.</s><s>The extracts were cleared by centrifugation for 30 min at 100,000 Â g.</s><s>The protein content was determined using the bicinchoninic acid assay (BCA) method <ref type="bibr" target="#b47">(Smith et al., 1985)</ref>.</s><s>Synthesis and characterization of the SAHA-CC (Supplemental Figure <ref type="figure">S1</ref>) and CCMS experiments (Supplementary Figure <ref type="figure" target="#fig_0">S2</ref>) were performed as previously described <ref type="bibr" target="#b14">(Fischer et al., 2011b)</ref>.</s></p><p><s>Briefly, 114 mg of total protein was used for each sample.</s><s>The SAHA-CC and free SAHA as competitor were employed at a final concentration of 10 mM and of 56 mM, respectively.</s><s>Capture assays, competition control samples, and bead controls (without CC) were prepared in hexaplicate from four SAHA resistant and four SAHA sensitive cell lines.</s></p><p><s>Experimental conditions for CCMS were designed to identify both high and moderate affinity SAHA binding proteins.</s><s>Buffer conditions were chosen that most likely native proteineprotein interactions were preserved throughout all steps of the experiment.</s><s>Under these conditions, primary SAHA binders can be specifically captured along with their proteineprotein interaction partners.</s></p><p><s>The captured proteins were proteolyzed and subjected to analysis by nanoflow liquid chromatography-tandem mass spectrometry (nLC-MS/MS).</s><s>For the identification and quantification of protein intensities across the different samples from the different cell lines, the software package MaxQuant was used, applying the label-free quantification option <ref type="bibr" target="#b8">(Cox and Mann, 2008)</ref>.</s><s>Further details on dose-dependent CCMS experiments, cross-competition studies, kinase assay, nLC-MS/ MS, data acquisition and analysis are described in Supplemental Methods (sections 1.2e1.6).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4.">Whole-exome sequencing, data analysis and validation</head><p><s>Whole-exome library preparation and sequencing of the 26 Bcell lymphoma cell lines was performed as described <ref type="bibr" target="#b4">(Chen et al., 2013)</ref>.</s><s>Briefly, exome capture was carried out using the SeqCap EZ Exome Library 2.0 kit (Roche/Nimblegen) and 100 bp single-read sequencing was performed on a HiSeq2500 (Illumina).</s><s>82% of the coding region was covered at least 30Â.</s><s>Data were analyzed as previously reported and described in detail in the Supplemental Methods section 1.7 <ref type="bibr" target="#b4">(Chen et al., 2013)</ref>.</s><s>Whole-exome sequencing data were deposited at the European Genome-phenome Archive (EGA, http://www.ebi.ac.uk/ega/), which is hosted by the EBI under the accession number EGAS00001001463.</s><s>Randomly chosen nucleotide variations (n ¼ 69) were validated by PCR and Sanger sequencing as described <ref type="bibr" target="#b4">(Chen et al., 2013)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5.">Integrated network analysis</head><p><s>To construct a proteineprotein interaction network of all proteins detected in the SAHA capture experiments, we used</s></p><p><s>Figure <ref type="figure">1</ref> e DETECT workflow.</s><s>In order to detect factors responsible for drug resistance, drug efficacy testing, exome mutation analysis and the determination of direct drug targets using CCMS are employed.</s></p><p><s>An integrative network analysis of these data reveals potential candidates.</s><s>Subsequently candidates are validated.</s></p><p><s>StringDB <ref type="bibr" target="#b17">(Franceschini et al., 2013)</ref>.</s><s>Medium confidence interactions (&gt;0.4) were taken into account, if they were not solely based on text mining methods.</s></p><p><s>To incorporate the exome data, we considered a ranking of possible effects of mutations as defined by the Ensembl analysis group (Supplemental Table <ref type="table">S2</ref>) and determined which gene carries more detrimental mutations in SAHA resistant compared to SAHA sensitive cells <ref type="bibr" target="#b16">(Flicek et al., 2014;</ref><ref type="bibr" target="#b33">McLaren et al., 2010)</ref>.</s><s>Only mutations with a frequency of less than 15% in the 1000 genomes project were considered to remove common variations.</s><s>Different attributes from CCenrichment and whole exome analysis were mapped to the graph and visualized using Cytoscape <ref type="bibr" target="#b46">(Shannon et al., 2003)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.6.">Protein extraction and Western blot analyses</head><p><s>Protein extraction and Western blot analysis were performed as described previously <ref type="bibr" target="#b10">(Dimitrova et al., 2014)</ref>.</s><s>The primary antibodies used for Western blot analysis were anti-FGR (clone 1B12; Abnova) and anti-beta actin (AC-15; Abcam).</s><s>The secondary goat anti-mouse IgG/HRP antibody was purchased from Dako (P0447) and the donkey anti-rabbit IgG/ HRP antibody from GE Healthcare Life Sciences (NA9340).</s></p><p><s>Western blot bands were quantified with the FusionCapt Advance software (Vilber Lourmat).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.7.">RNA isolation, cDNA synthesis and real-time reverse transcriptase (RT) polymerase chain reaction (PCR)</head><p><s>RNA was isolated and cDNA synthesized as described previously <ref type="bibr" target="#b24">(Joosten et al., 2013)</ref>.</s><s>Real-time RT PCR was performed with SYBR Green PCR-Master Mix (Applied Biosystems) by a StepOnePlus real-time PCR system (Applied Biosystems) using the PCR parameters recommended by the manufacturer.</s><s>The housekeeping gene GAPDH was amplified in parallel with FGR (FGR: forward: 5 0 -GGCCCGGCCTGCAT-3 0 ; reverse: 5 0 -TTGATGGCCTGAGAGGAGAAG-3 0 ; GAPDH: forward: 5 0 -AGGTGGAGGAGTGGGTGTCGCTGTT-3 0 ; reverse: 5 0 -CCGGGAAACTGTGGCGTGATGG-3 0 ).</s><s>Primers were purchased from Eurofins MWG.</s><s>Relative mRNA quantification was calculated using the comparative DDC T method <ref type="bibr" target="#b1">(Bookout and Mangelsdorf, 2003)</ref>.</s><s>A two-sided Mann Whitney U test was employed to test significant differences in FGR expression between SAHA resistant and sensitive cell lines.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.8.">FGR knock-out by CRISPR/Cas9</head><p><s>Knock-out of the FGR gene was done by CRISPR/Cas9 mediated double strand breaks leading to insertions/deletions after repair via the non-homologous end-joining pathway <ref type="bibr" target="#b7">(Cong et al., 2013;</ref><ref type="bibr" target="#b31">Mali et al., 2013)</ref>.</s><s>The heterogeneous genotype of the FGR locus in the resulting cell populations was analyzed by amplicon sequencing.</s><s>Methodical details are provided in Supplemental Methods (section 1.8).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2.9.</head><p><s>In silico FGR expression and mutation analysis in B-cell lymphoma patients</s></p><p><s>For the analysis of publicly available gene expression data sets of B-cell lymphoma samples (n ¼ 1200) the R2 application was used (R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl))</s><s><ref type="bibr" target="#b9">(Dave et al., 2006;</ref><ref type="bibr">Hummel et al., 2006;</ref><ref type="bibr" target="#b40">Richter et al., 2012;</ref><ref type="bibr">Scholtysik et al., 2015;</ref><ref type="bibr" target="#b52">Visco et al., 2012)</ref>.</s><s>For compilation of published tumor associated somatic nucleotide variations in B-cell lymphoma samples (n ¼ 413) the cosmic database (v74) was employed <ref type="bibr" target="#b17">(Forbes et al., 2015)</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.1.</head><p><s>Determination of SAHA resistant and sensitive Bcell lymphoma cell lines 26 B-cell lymphoma cell lines were treated with increasing concentrations of SAHA for 48 h.</s><s>Cell lines with IC50 values !2.5 mM SAHA were classified as resistant and cell lines with IC50 values 2.0 mM SAHA as sensitive.</s><s>Cell lines with IC50 values between 2.0 and 2.5 mM were classified as intermediate.</s><s>Classification was based on the average plasma concentration of SAHA in patients (2.5 mM) <ref type="bibr" target="#b23">(Iwamoto et al., 2013)</ref>.</s><s>According to these categories, we identified 11 SAHA resistant, 3 intermediate and 12 SAHA sensitive B-cell lymphoma cell lines (Table <ref type="table" target="#tab_0">1</ref>).</s><s>The IC 50 of the most resistant cell line (CA-46; IC 50 : 470.4 mM SAHA) differed from the IC 50 of the most sensitive cell line (OCI-Ly1; IC 50 : 0.5 mM SAHA) by three orders of magnitude.</s></p><formula xml:id="formula_0">M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 1 2 3 2 e1 2 4 4 3.2.</formula><p><s>CCMS based SAHA interaction profiles in SAHA resistant and SAHA sensitive cell lines Following the hypothesis that alterations in the capture profiles of proteins or protein complexes interacting with SAHA contribute to the differential SAHA response of the cells, we profiled the four most SAHA resistant and four of the most SAHA sensitive cells lines for SAHA-binding proteins by CCMS.</s></p><p><s>We compiled a list of 315 candidate proteins that directly or indirectly interact with SAHA.</s><s>This list contained previously described bona fide targets of SAHA (HDAC1, 2, 3, 6, 8, members of the HDAC1/2 complexes, ISOC1 and ISOC2) and a large number of novel proteins with unknown relation to HDACs (Supplementary Table <ref type="table">S3A</ref>) <ref type="bibr" target="#b0">(Bantscheff et al., 2011;</ref><ref type="bibr" target="#b14">Fischer et al., 2011b)</ref>.</s><s>Out of the 315 proteins compiled in our initial list, 129 were either predominantly enriched from SAHA  <ref type="bibr" target="#b16">(Flicek et al., 2014)</ref>.</s><s>Edge opaqueness expresses protein interaction confidence.</s><s>FGR showed significantly higher binding in all resistant cell lines during protein capture and carried more detrimental mutations in some resistant cell lines (3/11).</s><s>Data were visualized using Cytoscape.</s><s>The full graph is available as Supplemental Figure <ref type="figure" target="#fig_1">S3</ref>.</s><s>B: Normalized mass spectrometric protein intensities for FGR across SAHA CCMS assay with and without SAHA competition across four SAHA resistant and four sensitive cell lines.</s><s>The higher FGR enrichment by the SAHA-CC in resistant cell lines compared to sensitive cell lines was significant ( p [ 9.6 3 10 L7 ).</s><s>Regarding SAHA resistant cell lines, FGR enrichment was significantly higher in the SAHA CCMS assay with competitor as compared to SAHA capture assay without competitor (*p &lt; 0.05; **p &lt; 0.001).</s><s>Assay: SAHA CCMS assay without competitor, Competition: SAHA CCMS in the presence of a 5.6-fold excess of unmodified SAHA as competitor.</s><s>FGR protein intensities were determined by nLC-MS/MS followed by label-free quantification and data normalization.</s></p><p><s>resistant (n ¼ 117) or from SAHA sensitive (n ¼ 12) cell lines (Supplemental Table <ref type="table">S3B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3.">Integrated network analysis reveals FGR as a candidate involved in SAHA resistance</head><p><s>To assess the functional context of significant SAHA binders, we generated a proteineprotein interaction network from the 315 candidate proteins, which yielded 125 proteins that interact with each other (Supplemental Figure <ref type="figure" target="#fig_1">S3</ref>).</s><s>Interestingly, in the largest connected subnetwork, a membrane associated and cytoplasmic network comprising mainly Src kinases (FGR, HCK, LYN), G-proteins and their regulators (GNAI1, GNAI2, GNAI3, GNG7, GNAZ, GNAS, GNB1, RGS14 and RGS19) was linked to nucleus-associated HDAC-complexes through the STAT-pathway (Figure <ref type="figure" target="#fig_0">2A</ref>, Supplemental Figure <ref type="figure" target="#fig_1">S3</ref>).</s><s>The integration of our exome data into this network revealed three proteins (FGR, RGS14, and PAG1), which carry more detrimental mutations according to the Ensembl analysis group in a small number of resistant cell lines (FGR: 3/11; RGS14: 2/11, PAG1: 1/11) (Figure <ref type="figure" target="#fig_0">2A</ref>; Supplemental Figure <ref type="figure" target="#fig_1">S3</ref>; Supplemental Tables <ref type="table">S4 and S5</ref>) <ref type="bibr" target="#b16">(Flicek et al., 2014;</ref><ref type="bibr" target="#b33">McLaren et al., 2010)</ref>.</s><s>Among these proteins, FGR showed the highest and most significant (p ¼ 9.6 Â 10 À7 ) CCMS enrichment in resistant cells compared to sensitive cells (Figure <ref type="figure" target="#fig_0">2B</ref>; Supplemental Table <ref type="table">S3</ref>).</s><s>Taken together, our integrated network analysis identified networks of resistance mechanisms rather than single recurrent mutation.</s><s>The highly significant CCMS intensity profile of FGR in all resistant cell lines prompted us to investigate the role of FGR in SAHA resistance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4.">Characterization of the SAHA-FGR interaction</head><p><s>To the best of our knowledge, FGR has never been reported before to interact with SAHA.</s><s>Therefore, we characterized SAHA binding to FGR in more detail.</s><s>First, we determined FGR binding strength to SAHA.</s><s>To this end, a series of CCMS experiments with Raji cell lysate were performed, at which the protein input was constant, but the SAHA-CC concentration varied from 0 to 10 mM across 14 different concentrations.</s><s>The normalized mass spectrometric intensities of each individual protein across capture assays at the different concentrations of SAHA-CC determined by nLC-MS/MS yielded protein intensity profiles for each protein.</s><s>The analysis of these intensity profiles revealed two clusters of proteins with (i) high (half-maximal capturing between 250 and 500 nM SAHA-CC) and (ii) moderate affinity (half-maximal capturing between 1 and 10 mM SAHA-CC).</s><s>The high affinity cluster contained 24 proteins including several HDACs (e.g.</s><s>HDAC1 and HDAC6) and HDAC protein interaction partners (Supplemental Figure <ref type="figure" target="#fig_2">S4</ref>).</s><s>FGR was assigned to the moderate affinity cluster containing 78 proteins (Supplemental Figure <ref type="figure" target="#fig_3">S5</ref>).</s><s>For FGR, half-maximal capturing occurred at a CC-concentration of w2.5 mM compared to HDAC1 and HDAC6 with w350 nM, and w500 nM, respectively (Figure <ref type="figure" target="#fig_1">3A</ref>).</s><s>To estimate the apparent binding strength of SAHA to FGR, we determined the SAHA concentration required for half-maximal competition of the SAHA-CCbinding at a fixed SAHA-CC concentration of 2.5 mM.</s><s>Halfmaximal competition of the SAHA-CC binding to FGR occurred at a SAHA concentration of 5.1 mM compared to HDAC1 and HDAC6 with 0.97 mM, and 1.4 mM respectively (Figure <ref type="figure" target="#fig_1">3B</ref>).</s><s>These data confirmed that FGR is a SAHA binder with moderate affinity.</s></p><p><s>To prove direct binding of SAHA to FGR, we carried out CCMS experiments with purified human recombinant FGR.</s><s>The SAHA-CC comprised a photo-inducible cross-linking and a biotin-sorting functionality.</s><s>In case of direct SAHA binding, FGR should become biotinylated upon UV-induced crosslinking of the SAHA-CC.</s><s>This biotinylation should be abolished in the presence of an excess of SAHA as competitor.</s><s>As positive control and competitor, we used a dasatinib-CC and dasatinib respectively, since dasatinib is a known FGR inhibitor, which directly binds FGR with high affinity <ref type="bibr" target="#b12">(Fischer et al., 2011a;</ref><ref type="bibr" target="#b25">Karaman et al., 2008)</ref>.</s><s>Employing Western blot analysis, we showed direct cross-linking of SAHA-CC to FGR, which was abolished in the presence of SAHA comparable to the positive dasatinib control (Figure <ref type="figure" target="#fig_1">3C</ref>).</s><s>Thus, SAHA binds directly to FGR.</s></p><p><s>To test whether SAHA is capable of inhibiting FGR kinase activity, we performed an FGR kinase activity inhibition assay comparing dasatinib with SAHA.</s><s>While dasatinib inhibited FGR kinase activity in a low nM-range, SAHA was not able to inhibit FGR kinase activity even at the highest concentration tested (10 mM; data not shown).</s><s>Accordingly, direct binding of SAHA to FGR can only be explained by a direct binding of SAHA to FGR via a binding site different from dasatinib.</s><s>To this end, we tested whether the FGR binding sites for SAHA and dasatinib differ from each other.</s><s>We conducted CCMS experiments using the SAHA-CC and performed competition experiments with either SAHA or dasatinib employing a CA-46 cell lysate.</s><s>While SAHA largely abolished capturing of FGR by the SAHA-CC, capturing of FGR was only negligibly affected by dasatinib (Supplemental Figure <ref type="figure">S6</ref>).</s><s>The data further support that SAHA binds FGR directly and specifically, but that the SAHA binding site is different from the dasatinib binding site.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>3.5.</head><p><s>FGR expression status distinguished SAHA resistant from SAHA sensitive cell lines Since FGR showed the highest and most significant CCenrichment in resistant cells compared to sensitive cells, we analyzed FGR RNA/protein expression in our B-cell lymphoma cell line panel (n ¼ 26).</s><s>FGR protein expression was clearly higher in SAHA resistant cell lines compared to SAHA sensitive cell lines (Figure <ref type="figure" target="#fig_2">4A</ref>, Supplemental Table <ref type="table">S6</ref>).</s><s>In line with this, FGR RNA expression analysis in both groups revealed that the difference in FGR expression between resistant and sensitive cell lines was significant ( p ¼ 1.0 Â 10 À6 ) (Figure <ref type="figure" target="#fig_2">4B</ref>).</s><s>Thus, FGR expression is a strong indicator for SAHA resistance.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.6.">FGR knock-out leads to increased SAHA sensitivity in FGR non-mutated cell lines</head><p><s>To functionally validate the relation between FGR expression and SAHA resistance, three SAHA resistant cell lines (Daudi, Raji and DG-75) were chosen to knock-out FGR via CRISPR/ Cas9 targeting.</s><s>While Daudi and Raji have a non-mutated FGR gene, DG-75 harbors a heterozygous FGR mutation in its tyrosine kinase domain (c.1459/C&gt;A).</s><s>The resulting cell populations were composed of a heterogeneous genotype at the targeted locus with efficient FGR knock-out in Daudi (91% INDELs), and DG-75 (84.9% INDELs), while Raji only showed 51.8% INDELs (Figure <ref type="figure" target="#fig_3">5A</ref>; Supplemental Table <ref type="table">S7</ref>).</s></p><p><s>All cell lines were treated with different concentrations of SAHA (0e32 mM) to determine IC 50 values.</s><s>The lack of FGR clearly increased the sensitivity of Raji and Daudi to SAHA compared to control cells (Raji: 19.5 mM / 6.0 mM; Daudi: 287.2 mM / 55.9 mM; Figure <ref type="figure" target="#fig_3">5B</ref>).</s><s>Interestingly, the FGR mutated DG-75 cells showed no increase in SAHA sensitivity (117.5 mM / 132.5 mM; Figure <ref type="figure" target="#fig_3">5B</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.7.">FGR expression and mutation status in B-cell lymphoma patient samples</head><p><s>The expression of FGR in silico was analyzed in publicly available datasets of 1200 B-cell lymphoma patients using the R2 application (Figure <ref type="figure" target="#fig_2">4C</ref>) <ref type="bibr">(Hummel et al., 2006;</ref><ref type="bibr" target="#b40">Richter et al., 2012;</ref><ref type="bibr">Scholtysik et al., 2015;</ref><ref type="bibr" target="#b52">Visco et al., 2012)</ref>.</s><s>The expression of FGR in B-cell lymphoma samples was distributed over a wide log range within the analyzed cohorts.</s><s>This indicates that differences in FGR expression could potentially be used for a stratification of B-cell lymphoma patients prior to SAHA treatment.</s></p><p><s>We also analyzed publicly available sequencing data from 413 B-cell lymphoma patient samples <ref type="bibr" target="#b17">(Forbes et al., 2015)</ref>.</s><s>Only one of the samples harbored a mutation in FGR, which indicates that FGR mutations are very rare in primary B-cell lymphoma.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.">Discussion</head><p><s>The HDAC inhibitor SAHA showed encouraging clinical response rates in patients with refractory or relapsed B-cell lymphoma after SAHA monotherapy <ref type="bibr" target="#b28">(Kirschbaum et al., 2011;</ref><ref type="bibr" target="#b36">Ogura et al., 2014;</ref><ref type="bibr" target="#b53">Watanabe et al., 2010)</ref>.</s><s>Unfortunately, the majority of patients do not respond to this type of therapy posing the question for the underlying mechanisms.</s><s>Therefore, the understanding of these molecular resistance mechanisms could pave the way to stratify patients that benefit from a HDAC inhibitor therapy and thus improve the efficacy of these promising drugs.</s><s>We hypothesized that the therapeutic effect of a drug is mainly based on the expression and mutation status of drug target proteins.</s><s>To this end, we designed a novel approach combining drug efficacy testing with whole-exome data and captured target analysis (DETECT) to identify factors involved in drug resistance (Figure <ref type="figure">1</ref>).</s></p><p><s>Here, we used DETECT to unravel SAHA resistance mechanisms in a panel of 26 B-cell lymphoma cell lines as a model system for the molecular mechanisms in B-cell lymphoma.</s><s>While several studies have investigated mechanisms of HDAC resistance, so far direct binding proteins of SAHA were not examined in this context <ref type="bibr" target="#b11">(Fantin et al., 2008;</ref><ref type="bibr" target="#b15">Fiskus et al., 2008;</ref><ref type="bibr" target="#b18">Garcia-Manero et al., 2008;</ref><ref type="bibr" target="#b21">Ierano et al., 2013</ref>;  <ref type="bibr" target="#b26">Khan et al., 2010;</ref><ref type="bibr" target="#b27">Kim et al., 2015;</ref><ref type="bibr" target="#b30">Lee et al., 2011;</ref><ref type="bibr" target="#b35">Munster et al., 2009;</ref><ref type="bibr" target="#b51">Thompson et al., 2013)</ref>.</s><s>Furthermore, previous studies analyzing direct SAHA binding proteins did not focus on SAHA resistance mechanisms <ref type="bibr" target="#b0">(Bantscheff et al., 2011;</ref><ref type="bibr" target="#b14">Fischer et al., 2011b;</ref><ref type="bibr" target="#b43">Salisbury and Cravatt, 2007)</ref>.</s></p><p><s>Our SAHA sensitivity testing of B-cell lymphoma cell lines led to the identification of 11 SAHA resistant and 12 SAHA sensitive cell lines.</s><s>Both, BL and DLBCL cell lines were present in SAHA sensitive and resistant groups.</s><s>However, the BL cell lines showed the higher IC 50 values (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Overall, the observation of resistant and sensitive cell lines nicely reflects the occurrence of responding and non-responding B-cell lymphoma patients.</s></p><p><s>SAHA CCMS data of four SAHA resistant and four SAHA sensitive cell lines led to the identification of 315 SAHA binding proteins.</s><s>Combining the CCMS data with whole exome data of all 26 cell lines revealed a membrane associated and cytoplasmic subnetwork, comprising mainly membraneassociated Src kinases (FGR, HCK LYN) and G-proteins, linked to nucleus-associated HDAC-complexes through the STATpathway (Figure <ref type="figure" target="#fig_0">2A</ref> and Supplemental Figure <ref type="figure" target="#fig_1">S3</ref>).</s><s>Remarkably, mutations in FGR and its interaction partner RGS14 occurred in the same SAHA resistant cell lines (DG-75, HT) (Supplemental Table <ref type="table">S4</ref>).</s><s>Although multiple resistance factors are most likely involved in this SAHA relevant network, we focused on the role of FGR in SAHA resistance since it showed the highest and most significant CCMS enrichment.</s></p><p><s>First, we provided evidence of direct binding of SAHA to FGR and showed that the SAHA binding site for FGR must be different to the binding site of the FGR inhibitor dasatinib, which binds to the catalytic pocket.</s><s>However, the exact site of SAHA binding to FGR remains unclear (Figure <ref type="figure" target="#fig_1">3</ref>).</s></p><p><s>Next, we analyzed FGR expression in the 26 B-cell lymphoma cell lines (Figure <ref type="figure" target="#fig_2">4</ref> A/B; Supplemental Table <ref type="table">S6</ref>).</s><s>In line with our CCMS data, SAHA resistant cell lines showed a higher FGR expression and the difference in FGR expression between resistant and sensitive cell lines was significant for RNA and protein expression with p-values of 1.0 Â 10 À6 and GAPDH was used for normalization.</s><s>Note: Carnaval and Kis-1 showed increased CT values for GAPDH, which distort the quantitative FGR expression.</s><s>Thus, the average CT value for GAPDH (19.9) was used to normalize Carnaval and Kis-1.</s><s>Relative mRNA quantification was calculated using the comparative DDCT method <ref type="bibr" target="#b1">(Bookout and Mangelsdorf, 2003)</ref>.</s><s>Two-sided Mann-Whitney-U test revealed a significantly different FGR expression ( p [ 1.035 3 10 L6 ) in SAHA resistant cell lines compared to sensitive cell lines.</s><s>C: FGR expression is high and distributed over a wide range of B-cell lymphoma (n [ 1200).</s><s>Dot-boxplots present the log 2 transformed FGR expression values of B-cell lymphoma patients recruited in five independent cohorts.</s><s>Numbers of recruited patients are indicated.</s><s>Gene expression was determined using an Affymetrix U133P2 chip and MAS5 normalization <ref type="bibr">(Hummel et al., 2006;</ref><ref type="bibr" target="#b40">Richter et al., 2012;</ref><ref type="bibr">Scholtysik et al., 2015;</ref><ref type="bibr" target="#b52">Visco et al., 2012)</ref>.</s><s>In the Dave cohort, gene expression was analyzed using a custom oligonucleotide microarray with 2524 unique genes that are expressed differentially among a variety of non-Hodgkin lymphoma and MAS5 normalization <ref type="bibr" target="#b9">(Dave et al., 2006)</ref>.</s><s>Plots were generated using R2.</s></p><p><s>6.0 Â 10 À5 respectively.</s><s>However, FGR expression does not directly correlate with SAHA resistance, which might reflect the presence of multiple resistance factors.</s></p><p><s>To further prove the relation between FGR expression and SAHA resistance, we showed that FGR knock-out in SAHA resistant cell lines with high FGR expression led to increased SAHA sensitivity in non-mutated FGR cell lines.</s><s>It is of note, that SAHA sensitivity was not increased by FGR knock-out in DG-75 carrying the heterozygous mutation in the kinase domain of FGR (Supplemental Figure <ref type="figure">S7</ref>).</s><s>We speculate that DG-75 acquired mechanisms to circumvent a possible altered FGR function (Figure <ref type="figure" target="#fig_3">5</ref>).</s></p><p><s>In the context of B-cell lymphoma, the direct interaction of SAHA with FGR is of special interest.</s><s>FGR is clearly higher expressed in B-cell lymphoma cell lines compared to cell lines derived from non-lymphoid cancer entities (Supplemental Figure <ref type="figure">S8</ref>).</s><s>Furthermore, FGR is a member of Src-family kinases (SFKs) e a group of membrane-associated non-receptor tyrosine kinases e which are key mediators in the B-cell receptor signaling (BCR) transduction cascade <ref type="bibr" target="#b42">(Saijo et al., 2003)</ref>.</s><s>Other members of the SFKs are c-SRC, YES, FYN, LYN, LCK, HCK, BLK and YRK.</s><s>Interestingly, HCK and LYN were also present in our network of SAHA interacting proteins (Figure <ref type="figure" target="#fig_0">2A</ref>).</s><s>Activated Src kinases phosphorylate cytoplasmic domains of BCR components that finally lead to the activation of transcription factors such as nuclear factor-kB, nuclear factor of activated T-cells (NFAT) and signal transducers and activators of transcription (STATs) <ref type="bibr" target="#b38">(Dal Porto et al., 2004)</ref>.</s><s><ref type="bibr">Fantin et al.</ref> showed that SAHA resistant lymphoma cell lines (including B-and T-cell lymphoma) had higher expression levels of activated (phosphorylated) STAT1, STAT3 and STAT5 <ref type="bibr" target="#b11">(Fantin et al., 2008)</ref>.</s><s>Interestingly, FGR is involved in phosphorylation of STATs <ref type="bibr" target="#b45">(Schreiner et al., 2002)</ref>.</s><s>Moreover, our network analysis points towards a possible role of G-protein signaling being relevant for SAHA resistance mechanisms (Figure <ref type="figure" target="#fig_0">2A</ref>).</s></p><p><s>Since we focused on FGR, we further tested the feasibility using FGR analysis to stratify B-cell lymphoma patients.</s><s>For this purpose, we analyzed FGR expression and mutation status in silico by using publicly available data sets.</s><s>FGR expression analysis in 1200 B-cell lymphoma patients revealed a wide range of FGR expression (Figure <ref type="figure" target="#fig_2">4C</ref>).</s><s>FGR mutations were a rare event in B-cell lymphoma patients (n ¼ 1/413).</s><s>Therefore, FGR mutations seem to be negligible and FGR expression is a promising parameter to stratify patients that might benefit from SAHA therapy.</s></p><p><s>In conclusion, the novel DETECT approach is a comprehensive strategy to gain a better understanding of drug resistance mechanisms.</s><s>In this study, we describe a complex SAHA protein interaction network and identified FGR as a direct SAHA target protein being involved in SAHA resistance in B-cell lymphoma.</s><s>FGR expression might be helpful to stratify patients, who have a clinical benefit from SAHA treatment.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 e</head><label>2</label><figDesc><div><p><s>Figure2e FGR is a candidate for SAHA resistance in B-cell lymphoma.</s><s>A: Within the integrated network of captured proteins and whole exome sequencing data the node color and size indicate fold changes towards SAHA resistant (red) or sensitive (blue) cell lines in the CCMS experiments, white nodes indicate no relevant fold change (logFC&lt; 1), the transparency expresses the p-value.</s><s>Diamond shaped nodes mark gene products that carry a more detrimental mutation as defined by the Ensembl analysis group in any of the SAHA resistant cell lines<ref type="bibr" target="#b16">(Flicek et al., 2014)</ref>.</s><s>Edge opaqueness expresses protein interaction confidence.</s><s>FGR showed significantly higher binding in all resistant cell lines during protein capture and carried more detrimental mutations in some resistant cell lines (3/11).</s><s>Data were visualized using Cytoscape.</s><s>The full graph is available as Supplemental FigureS3.</s><s>B: Normalized mass spectrometric protein intensities for FGR across SAHA CCMS assay with and without SAHA competition across four SAHA resistant and four sensitive cell lines.</s><s>The higher FGR enrichment by the SAHA-CC in resistant cell lines compared to sensitive cell lines was significant ( p [ 9.6 3 10 L7 ).</s><s>Regarding SAHA resistant cell lines, FGR enrichment was significantly higher in the SAHA CCMS assay with competitor as compared to SAHA capture assay without competitor (*p &lt; 0.05; **p &lt; 0.001).</s><s>Assay: SAHA CCMS assay without competitor, Competition: SAHA CCMS in the presence of a 5.6-fold excess of unmodified SAHA as competitor.</s><s>FGR protein intensities were determined by nLC-MS/MS followed by label-free quantification and data normalization.</s></p></div></figDesc><graphic coords="5,136.01,197.46,318.72,409.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 e</head><label>3</label><figDesc><div><p><s>Figure 3 e Characterization of the SAHA-FGR interaction.</s><s>A: Binding of the SAHA-CC to FGR based on CCMS titration experiment with Raji protein lysate.</s><s>Half-maximal capturing of FGR by the SAHA-CC occurred at FGR [ w2.5 mM, HDAC1 w 375 nM, HDAC6 w 500 nM.</s><s>B: Dose-dependent competition of FGR with SAHA based on CCMS competition titration experiment at a fixed CC-concentration of 2.5 mM with Raji protein lysate.</s><s>Half-maximal competition occurred at FGR [ 5.10 mM, HDAC1 [ 970 nM, HDAC6 [ 1.40 mM.</s><s>The results of A and B suggest that SAHA binds to FGR with moderate affinity.</s><s>C: Streptavidin-horseradish peroxidase Western blot showing specific biotinylation of recombinant FGR (FGR-GST) by the SAHA-CC and dasatinib-CC (positive control).</s><s>The specific biotinylation by the SAHA-CC (final concentration 6.25 mM), which was abolished by the competitor (SAHA, final concentration 100 mM), indicates direct binding of SAHA to FGR.</s><s>In the reference experiment, the dasatinib-CC was used at 1.25 mM, and dasatinib (competitor) at 100 mM.</s><s>Western blots were documented using a G:BOX F3 Fluorescence Imaging System (Syngene).</s></p></div></figDesc><graphic coords="6,108.06,423.50,383.75,218.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 4 e</head><label>4</label><figDesc><div><p><s>Figure 4 e FGR expression.</s><s>A: Western blot analysis of B-cell lymphoma cell lines (n [ 26) revealed that FGR expression is higher in SAHA resistant cell lines compared to intermediate and sensitive cell lines.</s><s>b-actin was used as a loading control.</s><s>Fusion software (Peqlab Biotechnologie GmbH) was employed to analyze Western blot bands.</s><s>Narrow gaps indicate separately performed blots.</s><s>B: Real-time RT-PCR analysis of B-cell lymphoma cell lines (n [ 26) showed a higher expression of FGR in SAHA resistant cell lines compared to intermediate and sensitive cell lines.</s></p></div></figDesc><graphic coords="8,125.07,68.15,349.88,628.27" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 5 e</head><label>5</label><figDesc><div><p><s>Figure 5 e Functional validation of FGR involvement in SAHA resistance.</s><s>A: FGR knock-out (KO) in Raji, Daudi and DG-75 was confirmed by Western blot analysis.</s><s>Compared to control (untransfected) cells, all three FGR knock-out cell lines showed an efficient knock-out of FGR.</s><s>bactin was used as a loading control.</s><s>Fusion software (Peqlab Biotechnologie GmbH) was used to analyze Western blot bands.</s><s>B: SAHA IC50 values for control and FGR knock-out cell lines were determined.</s><s>Raji and Daudi (non-mutated FGR) showed an increase in SAHA sensitivity after FGR knock-out, whereas DG-75 (FGR mutation c.C1459A) had no change in SAHA sensitivity after FGR knock-out.</s><s>IC50 values were calculated using Prism6 (GraphPad Software, Inc.).</s></p></div></figDesc><graphic coords="9,118.15,68.15,354.43,242.59" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 e</head><label>1</label><figDesc><div><p><s>Categorization of 26 B-cell lymphoma cell lines in resistant, intermediate and sensitive based on their SAHA IC50 values.</s><s>IC50 values were calculated using Prism6 (GraphPad Software, Inc.).</s></p></div></figDesc><table><row><cell>SAHA</cell><cell>Cell line</cell><cell>IC50 (mM SAHA)</cell></row><row><cell>Resistant</cell><cell>CA-46*</cell><cell>470.40</cell></row><row><cell></cell><cell>Daudi*</cell><cell>282.60</cell></row><row><cell></cell><cell>DG-75*</cell><cell>117.70</cell></row><row><cell></cell><cell>Raji*</cell><cell>19.74</cell></row><row><cell></cell><cell>Blue-1</cell><cell>11.72</cell></row><row><cell></cell><cell>Namalwa</cell><cell>7.00</cell></row><row><cell></cell><cell>DND-39</cell><cell>5.76</cell></row><row><cell></cell><cell>HT</cell><cell>4.63</cell></row><row><cell></cell><cell>BL-70</cell><cell>3.93</cell></row><row><cell></cell><cell>Carnaval</cell><cell>3.56</cell></row><row><cell></cell><cell>WSU-DLCL2</cell><cell>3.52</cell></row><row><cell>Intermediate</cell><cell>Kis-1</cell><cell>2.49</cell></row><row><cell></cell><cell>SU-DHL-4</cell><cell>2.27</cell></row><row><cell></cell><cell>OCI-Ly7</cell><cell>2.15</cell></row><row><cell>Sensitive</cell><cell>OCI-Ly2</cell><cell>1.98</cell></row><row><cell></cell><cell>WSU-FSCCL</cell><cell>1.82</cell></row><row><cell></cell><cell>HBL-1</cell><cell>1.62</cell></row><row><cell></cell><cell>U2932</cell><cell>1.61</cell></row><row><cell></cell><cell>SU-DHL-6</cell><cell>1.48</cell></row><row><cell></cell><cell>Granta-452*</cell><cell>1.28</cell></row><row><cell></cell><cell>BL-2</cell><cell>1.18</cell></row><row><cell></cell><cell>OCI-Ly3</cell><cell>1.14</cell></row><row><cell></cell><cell>BL-41*</cell><cell>1.13</cell></row><row><cell></cell><cell>TMD8*</cell><cell>0.96</cell></row><row><cell></cell><cell>OCI-Ly10</cell><cell>0.61</cell></row><row><cell></cell><cell>OCI-Ly1*</cell><cell>0.50</cell></row></table><note><p><s>*cell lines used for CCMS analysis.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">M O L E C U L A R O N C O L O G Y1 0 ( 2 0 1 6 ) 1 2 3 2 e1 2 4 4</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank Hans-Henning M€ uller and Katayoun Alemazkour for excellent technical support, Georg Lenz for providing cell lines and Lora Dimitrova, Karsten Kleo, Dido Lenze, Marc Remke and Sefer Elezkurtaj for valuable discussion.</s></p><p><s>This work was supported by a grant from the "Zentrales Innovationsprojekt Mittelstand" (KF2766404CS2; KF2077503CS2; KF2986901CS2).</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure of conflicts of interest</head><p><s>All authors have no conflict of interest to disclose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>R E F E R E N C E S</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bantscheff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hopf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Savitski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dittmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grandi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Michon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schlegl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Becher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bergamini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boesche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dumpelfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Eberhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Huthmacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mathieson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Poeckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Reader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Strunk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sweetman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kruse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Neubauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Ramsden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Drewes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="255" to="e265" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Bookout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Mangelsdorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucl. Recept Signal</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">e012</biblScope>
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Budde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Shustov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pagel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Gooley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Knudsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Roden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Kammerer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Frayo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Warr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Boyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">W</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Gopal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Haematol</title>
		<imprint>
			<biblScope unit="volume">161</biblScope>
			<biblScope unit="page" from="183" to="e191" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Carew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Nawrocki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">269</biblScope>
			<biblScope unit="page" from="7" to="e17" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Next-generation-sequencing-based risk stratification and identification of new genes involved in structural and sequence variations in near haploid lymphoblastic leukemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartenhagen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gombert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Okpanyi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Binder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rottgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bradtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Teigler-Schlegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harbott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ginzel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dugas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Borkhardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="564" to="e579" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Histone deacetylase inhibitors in hematological malignancies and solid tumors</title>
		<author>
			<persName><forename type="first">P</forename><surname>Chun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch. Pharmacal Res</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="933" to="e949" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<monogr>
		<title level="m" type="main">Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP</title>
		<author>
			<persName><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Thieblemont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Den Neste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lepeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Plantier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Castaigne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lefort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Macro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sebban</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Belhadj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bordessoule</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ferme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tilly</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2010">2010. 2040e2045</date>
			<biblScope unit="volume">116</biblScope>
		</imprint>
	</monogr>
	<note>chemotherapy in DLBCL patients: a study by the Groupe d&apos;Etudes des Lymphomes de l&apos;Adulte. Blood</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Multiplex genome engineering using CRISPR/Cas systems</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">A</forename><surname>Ran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Barretto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Habib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Marraffini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="819" to="e823" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<date type="published" when="2008">2008. 1367e1372</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Dave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">W</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kluin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Boerma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Muller-Hermelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Delabie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Rimsza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Braziel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Grogan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Campo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Dave</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sanger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Vose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Armitage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Connors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Smeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kvaloy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Fisher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Montserrat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Staudt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">/</forename><surname>Lymphoma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia Molecular Profiling</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="page" from="2431" to="e2442" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>N. Engl. J. Med.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">PAX5 overexpression is not enough to reestablish the mature B-cell phenotype in classical Hodgkin lymphoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Dimitrova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Seitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szczepanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Oker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sommerfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jundt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="213" to="e216" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous Tcell lymphoma</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Fantin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loboda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Paweletz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Hendrickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Pierce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gooden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Korenchuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">S</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Randolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Ware</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Kadin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Richon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="3785" to="e3794" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dalhoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Schrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">Y</forename><surname>Graebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Andrich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Glinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sefkow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dreger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koester</surname></persName>
		</author>
		<title level="m">Dasatinib, imatinib and staurosporine capture compounds e complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS)</title>
				<imprint>
			<date type="published" when="2011">2011a</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">J. Proteomics</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="160" to="e168" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">SAHA Capture Compoundea novel tool for the profiling of histone deacetylases and the identification of additional vorinostat binders</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Michaelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Schrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Diehl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">Y</forename><surname>Graebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ungewiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Horzowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Glinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Kroll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dreger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Koester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteomics</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="4096" to="e4104" />
			<date type="published" when="2011">2011b</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells</title>
		<author>
			<persName><forename type="first">W</forename><surname>Fiskus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Herger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kolhe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mandawat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Joshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Eaton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Atadja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peiper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bhalla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="2896" to="e2905" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">P</forename><surname>Flicek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Amode</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Barrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Beal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Billis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Brent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carvalho-Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Clapham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Coates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fitzgerald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Giron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gordon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hourlier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Juettemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Kahari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Keenan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kulesha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maurel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Mclaren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Murphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Overduin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pignatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Riat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruffier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sheppard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thormann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Trevanion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vullo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Wilder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zadissa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Aken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Birney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Harrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Herrero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Hubbard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kinsella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muffato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spudich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Zerbino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Searle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<date type="published" when="2014">2014. 2014. D749eD755</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">COSMIC: exploring the world&apos;s knowledge of somatic mutations in human cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Forbes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Beare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gunasekaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bindal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Boutselakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bamford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cole</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Teague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Stratton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Mcdermott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><surname>D805ed811</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Franceschini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Szklarczyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Frankild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simonovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Minguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bork</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Von Mering</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Jensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nucleic Acids Res</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<date type="published" when="2013">2015. 2013. D808eD815</date>
		</imprint>
	</monogr>
	<note>Nucleic Acids Res</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Garcia-Manero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bueso-Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferrajoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">G</forename><surname>Wierda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faderl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Koller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loboda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Fantin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Randolph</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Hardwick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Secrist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">M</forename><surname>Richon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<date type="published" when="2008">2008. 1060e1066</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy</title>
		<author>
			<persName><forename type="first">D</forename><surname>Hoelzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Walewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Dohner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Viardot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Hiddemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Spiekermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Serve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Duhrsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Huttmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dengler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kneba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schaich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Schmidt-Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hertenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Reichle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Domanska-Czyz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fietkau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Horst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Rieder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Burmeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gokbuget</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="3870" to="e3879" />
			<date type="published" when="2014">2014</date>
		</imprint>
		<respStmt>
			<orgName>German Multicenter Study Group for Adult Acute Lymphoblastic, L</orgName>
		</respStmt>
	</monogr>
	<note>report of a large prospective multicenter trial</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche, K, 2006. A biologic definition of Burkitt&apos;s lymphoma from transcriptional and genomic profiling</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bentink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Berger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wessendorf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Barth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename><surname>Bernd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Cogliatti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dierlamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Feller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hansmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Haralambieva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hasenclever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Martin-Subero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Muller-Hermelink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Parwaresch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosolowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schwaenen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sturzenhofecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szczepanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Trautmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Wacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Spang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Trumper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<date>2419e2430</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors</title>
		<author>
			<persName><forename type="first">C</forename><surname>Ierano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Chakraborty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nicolae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Bahr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pittaluga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Robey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Cycle</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<date type="published" when="2013">2013. 2829e2838</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Epigenetic mechanisms of importance for drug treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ivanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Barragan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ingelman-Sundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Pharmacol. Sci</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="384" to="e396" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor</title>
		<author>
			<persName><forename type="first">M</forename><surname>Iwamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sandhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Agrawal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Rubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Wagner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemother. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="493" to="e508" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Histone acetylation and DNA demethylation of T cells result in an anaplastic large cell lymphoma-like phenotype</title>
		<author>
			<persName><forename type="first">M</forename><surname>Joosten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Seitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sommerfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Leser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="247" to="e254" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A quantitative analysis of kinase inhibitor selectivity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Karaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herrgard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Treiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gallant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Atteridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Campbell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ciceri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Edeen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Faraoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Floyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Lockhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">V</forename><surname>Milanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pallares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Wodicka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Zarrinkar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biotechnol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="127" to="e132" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy</title>
		<author>
			<persName><forename type="first">O</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fotheringham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Wood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Stimson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pezzella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Duvic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">B</forename><surname>La Thangue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U S A</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="page" from="6532" to="e6537" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Min</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Hyun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Lett</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<date type="published" when="2015">2015. 197e206</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin&apos;s lymphoma and mantle cell lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kirschbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Popplewell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Delioukina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pullarkat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Matsuoka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pulone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Espinoza-Delgado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nademanee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gandara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Newman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<date type="published" when="2011">2011. 1198e1203</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions</title>
		<author>
			<persName><forename type="first">H</forename><surname>Koster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Luan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Muller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Siddiqi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marappan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Yip</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Assay Drug Dev. Technol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="381" to="e390" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Choy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ngo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Venta-Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Marks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U S A</title>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<date type="published" when="2011">2011. 19629e19634</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">RNA-guided human genome engineering via Cas9</title>
		<author>
			<persName><forename type="first">P</forename><surname>Mali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Esvelt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Aach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Dicarlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Norville</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Church</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="823" to="e826" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Mann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Justice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pazdur</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncologist</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1247" to="e1252" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor</title>
		<author>
			<persName><forename type="first">W</forename><surname>Mclaren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pritchard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Flicek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cunningham</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<date type="published" when="2010">2010. 2069e2070</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia</title>
		<author>
			<persName><forename type="first">F</forename><surname>Morschhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Terriou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bachy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Varga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kloos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lelievre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Sarry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Depil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ribrag</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Investig. New Drugs</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="423" to="e431" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Munster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Thomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egorin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Minton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Springett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiappori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Daud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<date type="published" when="2009">2009. 1044e1050</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent Bcell non-Hodgkin lymphoma and mantle cell lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ogura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ando</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Suzuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ishizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Oh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Itoh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Au</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Tien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Terauchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Tanaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tobinai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">S</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Haematol</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="page" from="768" to="e776" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Oki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Buglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fanale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fayad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Copeland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Romaguera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>De Castro Faria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Neelapu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fowler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hagemeister</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Younes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="6882" to="e6890" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">B cell antigen receptor signaling 101</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Dal Porto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Gauld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Merrell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mills</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Pugh-Bernard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cambier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Immunol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="599" to="e613" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Novel therapeutic agents for B-cell lymphoma: developing rational combinations</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Reeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Ansell</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<date type="published" when="2011">2011. 1453e1462</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">J</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schlesner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kreuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Leich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Burkhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosolowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ammerpohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Wagener</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Bernhart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lenze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szczepanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paulsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lipinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adam-Klages</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Apic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Claviez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hasenclever</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Hovestadt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hornig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">O</forename><surname>Korbel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Langenberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lawerenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lisfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Picelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pischimarov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Radlwimmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Rausch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rohde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schilhabel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Scholtysik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Spang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Trautmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Zenz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Borkhardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Drexler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Macleod</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Trumper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">F</forename><surname>Stadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lichter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Eils</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kuppers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rosenstiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Project</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<date type="published" when="2012">2012. 1316e1320</date>
		</imprint>
	</monogr>
	<note>Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Richter-Larrea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Robles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Fresquet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Beltran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Rullan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Agirre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Calasanz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Panizo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Roman-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Prosper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Martinez-Climent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<date type="published" when="2010">2010. 2531e2542</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development</title>
		<author>
			<persName><forename type="first">K</forename><surname>Saijo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schmedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Karasuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Lowell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Reth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Adachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Patke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Santana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tarakhovsky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Immunol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="274" to="e279" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Activity-based probes for proteomic profiling of histone deacetylase complexes</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Salisbury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Cravatt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U S A</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<date type="published" when="2007">2007. 1171e1176</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche, K, 2015. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Scholtysik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kreuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hummel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosolowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Szczepanowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Klapper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Loeffler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Trumper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Siebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kuppers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="1033" to="e1042" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Schreiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Schiavone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Smithgall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Biol. Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="45680" to="e45687" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Cytoscape: a software environment for integrated models of biomolecular interaction networks</title>
		<author>
			<persName><forename type="first">P</forename><surname>Shannon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Markiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Ozier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Baliga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ramage</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Amin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schwikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ideker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genome Res</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<date type="published" when="2003">2003. 2498e2504</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Measurement of protein using bicinchoninic acid</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Siegel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jemal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">I</forename><surname>Krohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">T</forename><surname>Hermanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Mallia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Gartner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Provenzano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">K</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">M</forename><surname>Goeke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Olson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Klenk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">CA Cancer J. Clin</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="76" to="e85" />
			<date type="published" when="1985">2015. 2015. 1985</date>
		</imprint>
	</monogr>
	<note>Anal. Biochem.</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Straus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Hamlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Matasar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lia Palomba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Drullinsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Zelenetz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Gerecitano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Noy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Elstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wegner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wortman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br. J. Haematol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="663" to="e670" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Adult Burkitt&apos;s and Burkitt-like non-Hodgkin&apos;s lymphomaeoutcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Sweetenham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pearce</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Taghipour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Blaise</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gisselbrecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Goldstone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2465" to="e2472" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<monogr>
		<title level="m" type="main">WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organisation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Swerdlow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Campo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Jaffe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Pileri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Vadiman</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<pubPlace>Lyon</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Vardinogiannis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Gilmore</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PloS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<date type="published" when="2013">2013. e62822</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification</title>
		<author>
			<persName><forename type="first">C</forename><surname>Visco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Y</forename><surname>Xu-Monette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">N</forename><surname>Miranda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tzankov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Kahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Amore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Montes-Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dybkaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Orazi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bhagat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Winter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'neill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Dunphy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Hsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">F</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Go</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Czader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Van Krieken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Ai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Etzell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ponzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Ferreri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Piris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Moller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Bueso-Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Medeiros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Young</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<date type="published" when="2012">2012. 2103e2113</date>
		</imprint>
	</monogr>
	<note>in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yamasaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Morita-Hoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yokoyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Morishima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Ricker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Otsuki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Miyagi-Maesima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsuno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Tobinai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Sci</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<date type="published" when="2010">2010. 196e200</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">M</forename><surname>O L E C U L A R O N C O L O G Y 1</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molonc.2016.06.001</idno>
		<imprint/>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
